Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · colon-landscapes@1

SRR975601

—

f23e81b3-7ab2-55bd-89d3-5f4cecfbc925

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • BILE_ACID_METABOLISM+0.560
  • XENOBIOTIC_METABOLISM+0.540
  • COAGULATION+0.390
  • FATTY_ACID_METABOLISM+0.340
  • ADIPOGENESIS+0.310
  • KRAS_SIGNALING_DN+0.250
  • PEROXISOME+0.250
  • HEME_METABOLISM+0.210
  • OXIDATIVE_PHOSPHORYLATION+0.200
  • COMPLEMENT+0.180

Top 10 suppressed

  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.420
  • HEDGEHOG_SIGNALING-0.370
  • UNFOLDED_PROTEIN_RESPONSE-0.330
  • TNFA_SIGNALING_VIA_NFKB-0.310
  • NOTCH_SIGNALING-0.270
  • TGF_BETA_SIGNALING-0.250
  • WNT_BETA_CATENIN_SIGNALING-0.250
  • ANGIOGENESIS-0.210
  • E2F_TARGETS-0.210
  • APOPTOSIS-0.200

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MBCProject_0217_T2_RNA
breast-umap@18
—C0.820
2SRR15030860
colon-landscapes@1
——0.809
3SRR8752377
head-neck@1
——0.783
4SRR12696784
melanoma-umap@29
——0.766
5TCGA-OR-A5J6-01
acc-tcga-pancan-2018@2018
Adrenocortical CarcinomaAdrenocortical Carcinoma, Usual Type0.766
6AUR-AD9G-TTM2-A-1-1-R-A542-39
breast-umap@18
—C0.734
7TCGA-49-6742-01A-11R-1858-07
lung-landscapes@6
—cohortA40.724
8TCGA-67-3770-01A-01R-0946-07
lung-landscapes@6
—cohortA10.722
9BS_B6M763JS
brain-umap@2
subependymal giant cell astrocytoma(SEGA)—0.708
1020050003.LumA
breast-umap@18
—B0.708

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 19 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
BILE_ACID_METABOLISM0.560Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.540Inavolisib— uncovered
COAGULATION0.390Binimetinib— uncovered
FATTY_ACID_METABOLISM0.340Inavolisib— uncovered
ADIPOGENESIS0.310Inavolisib— uncovered
KRAS_SIGNALING_DN0.250Remibrutinib— uncovered
PEROXISOME0.250Idelalisib— uncovered
HEME_METABOLISM0.210Temsirolimus— uncovered
OXIDATIVE_PHOSPHORYLATION0.200Remibrutinib— uncovered
COMPLEMENT0.180Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.160Idelalisib— uncovered
INTERFERON_ALPHA_RESPONSE0.150Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.130Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.080Remibrutinib— uncovered
ESTROGEN_RESPONSE_EARLY0.080Inavolisib— uncovered
MTORC1_SIGNALING0.060Inavolisib— uncovered
PANCREAS_BETA_CELLS0.050Cobimetinib— uncovered
SPERMATOGENESIS0.050Inavolisib— uncovered
UV_RESPONSE_DN0.030Inavolisib— uncovered